TASTE
(2019)Objective
Tenecteplase versus alteplase in acute ischemic stroke.
Study Summary
• Higher doses of tenecteplase could potentially lead to better outcomes in terms of arterial recanalization and clinical recovery in stroke patients than standard alteplase treatment.
Intervention
Tenecteplase at a dose range of 0.1 to 0.4 mg/kg.
Inclusion Criteria
Patients treated within 4.5 hours of acute ischemic stroke symptom onset.
Study Design
Arms: Variable doses of Tenecteplase vs. standard dose Alteplase
Patients per Arm: Variable, depending on dose subgroup
Outcome
• In the Tenecteplase group, various doses showed that up to 59% of patients achieved functional independence at 90 days with a median mRS of 2, and sICH rates varied around 3%. <br>• The control group using Alteplase had 55% reaching functional independence, with a median mRS of 2.5 and sICH rates of 2.9%..